Feasibility Study of Docetaxel and Cyclophosphamide Six- Cycle Therapy as Adjuvant Chemotherapy for Japanese Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Patients |
Abe, Hajime
(Breast Center, Bell Land General Hospital)
Mori, Tsuyoshi (Division of Breast and General Surgery, Shiga University of Medical Science) Kawai, Yuki (Division of Breast and General Surgery, Shiga University of Medical Science) Tomida, Kaori (Division of Breast and General Surgery, Shiga University of Medical Science) Kubota, Yoshihiro (Division of Breast and General Surgery, Shiga University of Medical Science) Umeda, Tomoko (Division of Breast and General Surgery, Shiga University of Medical Science) Tani, Tohru (Department of Surgery, Shiga University of Medical Science) |
1 | Bonadonna G, Moliterni A, Zambetti M, et al (2005). 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ, 330, 217. DOI ScienceOn |
2 | Ganz PA, Land SR, Geyer CE Jr, et al (2011). Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol, 29, 1110-6. DOI ScienceOn |
3 | Iwata H, Sato N, Masuda N, et al (2011). Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer. Jpn J Clin Oncol, 41, 867-75. DOI ScienceOn |
4 | Jones SE, Savin MA, Holmes FA, et al (2006). Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol, 24, 5381-7. DOI ScienceOn |
5 | Jones S, Holmes FA, O’Shaughnessy J, et al (2009). Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol, 27, 1177-83. DOI ScienceOn |
6 | Martin M, Pienkowski T, Mackey J, et al (2005). Breast Cancer International Research Group 001 Investigators: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med, 352, 2302-13. DOI ScienceOn |
7 | Roche H, Fumoleau P, Spielmann M, et al (2006). Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol, 24, 5664-71. DOI ScienceOn |
8 | Takabatake D, Taira N, Hara F, et al (2009). Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for japanese breast cancer patients. Jpn J Clin Oncol, 39, 478-83. DOI ScienceOn |
9 | De Laurentiis M, Cancello G, D’Agostino D, et al (2008). Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol, 26, 44-53. DOI ScienceOn |
10 | Eiermann W, Pienkowski T, Crown J, et al (2011). Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2.normal, node-positive breast cancer: BCIRG-005 Trial. J Clin Oncol, 29, 3877-84. DOI ScienceOn |
11 | Fisher B, Jeong JH, Anderson S, et al (2004). Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. J Natl Cancer Inst, 96, 1823-31. DOI ScienceOn |
12 | Fumoleau P, Roche´ H, Kerbrat P, et al (2006). French adjuvant study group: long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol, 17, 85-92. DOI ScienceOn |
13 | Abe H, Mori T, Kawai Y, et al (2012). Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. Int J Clin Oncol, 18, 487-91. |
![]() |